Hefty drug price rises seen in Slovenia
New regulations on drug pricing in Slovenia have seen the prices of some medicines rise by as much as 98% in some cases, according to a local business newspaper.
The daily Finance reported that there had been a rise in the prices of many drugs. It highlighted such extreme examples as a 91% hike in the price of Plivit D3 vitamin drops for babies and a 98% increase in the price of certain sleeping pills.
The new regulations were introduced at the start of the year. The government claimed that they were designed to make it clearer to consumers which drugs were generic and which were original, brand-name products. Pharmacy-industry representatives have said that the higher prices for some medicines are in accord with the new pricing regulations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze